Webinar – Pain R&D: Plenty of Pain to Go Around, But Who’s Making Gains?

Despite a growing need for safe, effective pain drugs, the drug development pipeline is sparsely populated. Recent setbacks like those facing Lilly and Pfizer’s anti-NGF drug have chilled the atmosphere for new lines of research. In an Endpoints webinar on August 11th, Lei Lei Wu of Endpoints will sit down with Jan Adams of Grünenthal to discuss the situation and how to improve access to patients.

According to Endpoints Webinars, “ Always driven to improve patients’ lives, Jan Adams has built up more than 15 years of experience in healthcare and biopharmaceuticals and took over the role of CSO in 2020. Under his leadership, Grünenthal transformed its R&D strategy and operating model and significantly strengthened its pipeline of highly innovative non-opioid pain assets. Jan joined Grünenthal in July 2017 as Head of Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company’s global Pharmaceutical and Medical Products practice.”

To read more, click here.

(Source: Endpoints Webinars, July 21st, 2022)